Reverse Translational Research of ABCG2 (BCRP) in Human Disease and Drug Response

被引:27
作者
Brackman, Deanna J. [1 ]
Giacomini, Kathleen M. [1 ,2 ]
机构
[1] Univ Calif San Francisco, Dept Bioengn & Therapeut Sci, San Francisco, CA 94143 USA
[2] Univ Calif San Francisco, Inst Human Genet, San Francisco, CA 94143 USA
关键词
CANCER RESISTANCE PROTEIN; CELL LUNG-CANCER; BREAST-CANCER; MULTIDRUG-RESISTANCE; ROSUVASTATIN PHARMACOKINETICS; GENETIC POLYMORPHISMS; ALZHEIMERS-DISEASE; TRANSPORTER ABCG2; RISK-FACTORS; PHASE-II;
D O I
10.1002/cpt.903
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Reverse translational research takes a bedside-to-bench approach, using sophisticated basic research to explain the biological mechanisms behind observed clinical data. For transporters, which play a role in human disease and drug response, this approach offers a distinct advantage over the typical translational research, which often falters due to inadequate in vitro and preclinical animal models. Research on ABCG2, which encodes the Breast Cancer Resistance Protein, has benefited immensely from a reverse translational approach due to its broad implications for disease susceptibility and both therapeutic and adverse drug response. In this review, we describe the success of reverse translational research for ABCG2 and opportunities for further studies.
引用
收藏
页码:233 / 242
页数:10
相关论文
共 50 条
  • [21] Role of the Breast Cancer Resistance Protein (BCRP/ABCG2) in Drug Transport-an Update
    Mao, Qingcheng
    Unadkat, Jashvant D.
    AAPS JOURNAL, 2015, 17 (01): : 65 - 82
  • [22] ABCG2 (BCRP) expression in normal and malignant hematopoietic cells
    Abbott, BL
    HEMATOLOGICAL ONCOLOGY, 2003, 21 (03) : 115 - 130
  • [23] Suppression of ABCG2 mediated MDR in vitro and in vivo by a novel inhibitor of ABCG2 drug transport
    Patel, Atish
    Li, Tian-Wen
    Anreddy, Nagaraju
    Wang, De-Shen
    Sodani, Kamlesh
    Gadhia, Sanket
    Kathawala, Rishil
    Yang, Dong-Hua
    Cheng, Changmei
    Chen, Zhe-Sheng
    PHARMACOLOGICAL RESEARCH, 2017, 121 : 184 - 193
  • [24] The phytoestrogens daidzein and equol inhibit the drug transporter BCRP/ABCG2 in breast cancer cells: potential chemosensitizing effect
    Pablo Rigalli, Juan
    Scholz, Paul Niklas
    Nicolas Tocchetti, Guillermo
    Laura Ruiz, Maria
    Weiss, Johanna
    EUROPEAN JOURNAL OF NUTRITION, 2019, 58 (01) : 139 - 150
  • [25] Tariquidar-related triazoles as potent, selective and stable inhibitors of ABCG2 (BCRP)
    Antoni, Frauke
    Bause, Manuel
    Scholler, Matthias
    Bauer, Stefanie
    Stark, Simone A.
    Jackson, Scott M.
    Manolaridis, Ioannis
    Locher, Kaspar P.
    Koenig, Burkhard
    Buschauer, Armin
    Bernhardt, Guenther
    EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2020, 191
  • [26] Modulating Drug Resistance by Targeting BCRP/ABCG2 Using Retrovirus-Mediated RNA Interference
    Xie, Ni
    Mou, Lisha
    Yuan, Jianhui
    Liu, Wenlan
    Deng, Tingting
    Li, Zigang
    Jin, Yi
    Hu, Zhangli
    PLOS ONE, 2014, 9 (07):
  • [27] Transcription factor-mediated regulation of the BCRP/ABCG2 efflux transporter: a review across tissues and species
    Gorczyca, Ludwik
    Aleksunes, Lauren M.
    EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2020, 16 (03) : 239 - 253
  • [28] BCRP/ABCG2 inhibitors: a patent review (2009-present)
    Wiese, Michael
    EXPERT OPINION ON THERAPEUTIC PATENTS, 2015, 25 (11) : 1229 - 1237
  • [29] Synthesis and biological evaluation of flavones and benzoflavones as inhibitors of BCRP/ABCG2
    Juvale, Kapil
    Stefan, Katja
    Wiese, Michael
    EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2013, 67 : 115 - 126
  • [30] The ABCG2/BCRP transporter and its variants - from structure to pathology
    Sarkadi, Balazs
    Homolya, Laszlo
    Hegedus, Tamas
    FEBS LETTERS, 2020, 594 (23) : 4012 - 4034